Cargando…
After TGN1412: Recent developments in cytokine release assays
The failure of regulatory science to keep pace with and support the development of new biological medicines was very publically highlighted in March 2006 when the first-in-man Phase I clinical trial of the immunomodulatory CD28-specific monoclonal antibody (mAb) TGN1412 ended in disaster when all si...
Autores principales: | Stebbings, R., Eastwood, D., Poole, S., Thorpe, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Informa Healthcare
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541671/ https://www.ncbi.nlm.nih.gov/pubmed/22967038 http://dx.doi.org/10.3109/1547691X.2012.711783 |
Ejemplares similares
-
Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release
por: Eastwood, David, et al.
Publicado: (2013) -
Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials — Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm
por: Vessillier, S., et al.
Publicado: (2015) -
The GARDpotency Assay for Potency-Associated Subclassification of Chemical Skin Sensitizers—Rationale, Method Development, and Ring Trial Results of Predictive Performance and Reproducibility
por: Gradin, Robin, et al.
Publicado: (2020) -
TGN1412: From Discovery to Disaster
por: Attarwala, H
Publicado: (2010) -
Amiodarone Exposure During Modest Inflammation Induces Idiosyncrasy-like Liver Injury in Rats: Role of Tumor Necrosis Factor-alpha
por: Lu, Jingtao, et al.
Publicado: (2012)